Mechanisms of mTOR inhibitor resistance in cancer therapy

Targeted Oncology

Volumn 6, Issue 1, 2011, Pages 17-27

  Carew, Jennifer S ^a   Kelly, Kevin R ^a   Nawrocki, Steffan T ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Apoptosis; Autophagy; Drug resistance; mTOR Inhibitor; PIM kinase; Rapamycin

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ARSENIC TRIOXIDE; BORTEZOMIB; CHLOROQUINE; CYCLIN D1; ETOPOSIDE; EVEROLIMUS; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NAVITOCLAX; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PP 242; PROTEIN KINASE B; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RIDAFOROLIMUS; SORAFENIB; TAMOXIFEN; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; CANCER RESISTANCE; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE MUTATION; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; MANTLE CELL LYMPHOMA; MELANOMA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANTIBIOTICS, ANTINEOPLASTIC; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 79957530990     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-011-0167-8     Document Type: Review

References (112)

1. R Loewith E Jacinto S Wullschleger A Lorberg JL Crespo D Bonenfant W Oppliger P Jenoe MN Hall 2002 Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control Mol Cell 10 457 468 12408816 1:CAS:528:DC%2BD38XnvFSlt74%3D (Pubitemid 35284167)
2. K Hara Y Maruki X Long K Yoshino N Oshiro S Hidayat C Tokunaga J Avruch K Yonezawa 2002 Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action Cell 110 177 189 12150926 1:CAS:528:DC%2BD38XlvV2htr8%3D (Pubitemid 34876546)
3. DH Kim DD Sarbassov SM Ali JE King RR Latek H Erdjument-Bromage P Tempst DM Sabatini 2002 mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery Cell 110 163 175 12150925 1:CAS:528:DC%2BD38XlvV2htr4%3D (Pubitemid 34876545)
4. TR Peterson M Laplante CC Thoreen Y Sancak SA Kang WM Kuehl NS Gray DM Sabatini 2009 DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival Cell 137 873 886 19446321 1:CAS:528:DC%2BD1MXosVCltb0%3D
5. Y Sancak CC Thoreen TR Peterson RA Lindquist SA Kang E Spooner SA Carr DM Sabatini 2007 PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase Mol Cell 25 903 915 17386266 1:CAS:528:DC%2BD2sXktFCgsbc%3D (Pubitemid 46436534)
6. E Vander Haar SI Lee S Bandhakavi TJ Griffin DH Kim 2007 Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 Nat Cell Biol 9 316 323 17277771 1:CAS:528:DC%2BD2sXit12rsr0%3D (Pubitemid 46344611)
7. J Choi J Chen SL Schreiber J Clardy 1996 Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP Science 273 239 242 8662507 1:CAS:528:DyaK28Xkt1Crs7k%3D (Pubitemid 26285890)
8. E Jacinto R Loewith A Schmidt S Lin MA Ruegg A Hall MN Hall 2004 Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive Nat Cell Biol 6 1122 1128 15467718 1:CAS:528:DC%2BD2cXptFentL8%3D (Pubitemid 39468014)
9. DD Sarbassov SM Ali DH Kim DA Guertin RR Latek H Erdjument-Bromage P Tempst DM Sabatini 2004 Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton Curr Biol 14 1296 1302 15268862 1:CAS:528:DC%2BD2cXmtVamsLs%3D (Pubitemid 38991819)
10. DD Sarbassov SM Ali S Sengupta JH Sheen PP Hsu AF Bagley AL Markhard DM Sabatini 2006 Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB Mol Cell 22 159 168 16603397 1:CAS:528:DC%2BD28Xkt1GmtLo%3D
11. X Long Y Lin S Ortiz-Vega K Yonezawa J Avruch 2005 Rheb binds and regulates the mTOR kinase Curr Biol 15 702 713 15854902 1:CAS:528: DC%2BD2MXjsFKiu7o%3D (Pubitemid 40599924)
12. HB Jefferies S Fumagalli PB Dennis C Reinhard RB Pearson G Thomas 1997 Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k EMBO J 16 3693 3704 9218810 1:CAS:528:DyaK2sXktlCnsLw%3D (Pubitemid 27250062)
13. MK Holz BA Ballif SP Gygi J Blenis 2005 mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events Cell 123 569 580 16286006 1:CAS:528: DC%2BD2MXht1yktrvK (Pubitemid 41608461)
14. B Raught F Peiretti AC Gingras M Livingstone D Shahbazian GL Mayeur RD Polakiewicz N Sonenberg JW Hershey 2004 Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases EMBO J 23 1761 1769 15071500 1:CAS:528:DC%2BD2cXjt1Cls7Y%3D (Pubitemid 38649639)
15. S Faivre G Kroemer E Raymond 2006 Current development of mTOR inhibitors as anticancer agents Nat Rev Drug Discov 5 671 688 16883305 1:CAS:528: DC%2BD28XnsFCkurk%3D (Pubitemid 44151605)
16. MA Bjornsti PJ Houghton 2004 The TOR pathway: a target for cancer therapy Nat Rev Cancer 4 335 348 15122205 1:CAS:528:DC%2BD2cXjsFSlu7Y%3D (Pubitemid 38579480)
17. PK Majumder PG Febbo R Bikoff R Berger Q Xue LM McMahon J Manola J Brugarolas TJ McDonnell TR Golub M Loda HA Lane WR Sellers 2004 mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways Nat Med 10 594 601 15156201 1:CAS:528:DC%2BD2cXksVais7w%3D (Pubitemid 38796850)
18. MM Mita A Mita EK Rowinsky 2003 The molecular target of rapamycin (mTOR) as a therapeutic target against cancer Cancer Biol Ther 2 S169 177 14508096 1:CAS:528:DC%2BD2cXis1Knug%3D%3D
19. G Hudes M Carducci P Tomczak J Dutcher R Figlin A Kapoor E Staroslawska J Sosman D McDermott I Bodrogi Z Kovacevic V Lesovoy IG Schmidt-Wolf O Barbarash E Gokmen T O'Toole S Lustgarten L Moore RJ Motzer 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271 2281 17538086 1:CAS:528:DC%2BD2sXmtVKkurs%3D (Pubitemid 46849157)
20. RJ Motzer B Escudier S Oudard TE Hutson C Porta S Bracarda V Grunwald JA Thompson RA Figlin N Hollaender G Urbanowitz WJ Berg A Kay D Lebwohl A Ravaud 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 449 456 18653228 1:CAS:528:DC%2BD1cXps1GmsLY%3D
21. MS Neshat IK Mellinghoff C Tran B Stiles G Thomas R Petersen P Frost JJ Gibbons H Wu CL Sawyers 2001 Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc Natl Acad Sci USA 98 10314 10319 11504908 1:CAS:528:DC%2BD3MXmvFWiurk%3D (Pubitemid 32803017)
22. K Podsypanina RT Lee C Politis I Hennessy A Crane J Puc M Neshat H Wang L Yang J Gibbons P Frost V Dreisbach J Blenis Z Gaciong P Fisher C Sawyers L Hedrick-Ellenson R Parsons 2001 An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice Proc Natl Acad Sci USA 98 10320 10325 11504907 1:CAS:528:DC%2BD3MXmvFWiurY%3D (Pubitemid 32803018)
23. E Galanis JC Buckner MJ Maurer JI Kreisberg K Ballman J Boni JM Peralba RB Jenkins SR Dakhil RF Morton KA Jaeckle BW Scheithauer J Dancey M Hidalgo DJ Walsh 2005 Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study J Clin Oncol 23 5294 5304 15998902 1:CAS:528:DC%2BD2MXpslOrtLw%3D (Pubitemid 46206983)
24. K Margolin J Longmate T Baratta T Synold S Christensen J Weber T Gajewski I Quirt JH Doroshow 2005 CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium Cancer 104 1045 1048 16007689 1:CAS:528:DC%2BD2MXhtVWqsLbF (Pubitemid 41170233)
25. F Di Nicolantonio S Arena J Tabernero S Grosso F Molinari T Macarulla M Russo C Cancelliere D Zecchin L Mazzucchelli T Sasazuki S Shirasawa M Geuna M Frattini J Baselga M Gallicchio S Biffo A Bardelli 2010 Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus J Clin Invest 120 2858 2866 20664172
26. WG Kaelin Jr. 2007 The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma Clin Cancer Res 13 680s 684s 17255293 1:CAS:528:DC%2BD2sXoslSrug%3D%3D
27. M Ohh CW Park M Ivan MA Hoffman TY Kim LE Huang N Pavletich V Chau WG Kaelin 2000 Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein Nat Cell Biol 2 423 427 10878807 1:CAS:528:DC%2BD3cXkvFCqtrk%3D
28. D Mahalingam EC Medina JA Esquivel 2nd CM Espitia S Smith K Oberheu R Swords KR Kelly MM Mita AC Mita JS Carew FJ Giles ST Nawrocki 2010 Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels Clin Cancer Res 16 141 153 20028765 1:CAS:528:DC%2BC3cXotFyk
29. TE Witzig SM Geyer I Ghobrial DJ Inwards R Fonseca P Kurtin SM Ansell R Luyun PJ Flynn RF Morton SR Dakhil H Gross SH Kaufmann 2005 Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma J Clin Oncol 23 5347 5356 15983389 1:CAS:528:DC%2BD2MXpslOrtLk%3D (Pubitemid 46206988)
30. FJ Dumont MJ Staruch T Grammer J Blenis CA Kastner KM Rupprecht 1995 Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma Cell Immunol 163 70 79 7538911 1:CAS:528:DyaK2MXlvFejsL0%3D
31. DA Fruman MA Wood CK Gjertson HR Katz SJ Burakoff BE Bierer 1995 FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells Eur J Immunol 25 563 571 7533090 1:CAS:528:DyaK2MXktVOrurs%3D
32. MC Lorenz J Heitman 1995 TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin J Biol Chem 270 27531 27537 7499212 1:CAS:528:DyaK2MXpsFShsbw%3D
33. ME Feldman B Apsel A Uotila R Loewith ZA Knight D Ruggero KM Shokat 2009 Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 PLoS Biol 7 e38 19209957
34. CC Thoreen SA Kang JW Chang Q Liu J Zhang Y Gao LJ Reichling T Sim DM Sabatini NS Gray 2009 An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 J Biol Chem 284 8023 8032 19150980 1:CAS:528:DC%2BD1MXjtVSmtLY%3D
35. K Yu L Toral-Barza C Shi WG Zhang J Lucas B Shor J Kim J Verheijen K Curran DJ Malwitz DC Cole J Ellingboe S Ayral-Kaloustian TS Mansour JJ Gibbons RT Abraham P Nowak A Zask 2009 Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin Cancer Res 69 6232 6240 19584280 1:CAS:528:DC%2BD1MXpt1CgtbY%3D
36. AP Bhatt PM Bhende SH Sin D Roy DP Dittmer B Damania 2010 Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas Blood 115 4455 4463 20299510 1:CAS:528:DC%2BC3cXnsFKnt7c%3D
37. MG Kharas MR Janes VM Scarfone MB Lilly ZA Knight KM Shokat DA Fruman 2008 Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells J Clin Invest 118 3038 3050 18704194 1:CAS:528:DC%2BD1cXhtV2isb3M
38. Y Shi H Yan P Frost J Gera A Lichtenstein 2005 Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade Mol Cancer Ther 4 1533 1540 16227402 1:CAS:528:DC%2BD2MXhtFWhtLjE (Pubitemid 41556435)
39. J Tamburini N Chapuis V Bardet S Park P Sujobert L Willems N Ifrah F Dreyfus P Mayeux C Lacombe D Bouscary 2008 Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways Blood 111 379 382 17878402 1:CAS:528:DC%2BD1cXjtVKmtQ%3D%3D
40. DD Sarbassov DA Guertin SM Ali DM Sabatini 2005 Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 1098 1101 15718470 1:CAS:528:DC%2BD2MXhtlSrtbY%3D (Pubitemid 40262113)
41. M Gupta SM Ansell AJ Novak S Kumar SH Kaufmann TE Witzig 2009 Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2 Blood 114 2926 2935 19641186 1:CAS:528:DC%2BD1MXht12qur%2FJ
42. F Chiarini C Grimaldi F Ricci PL Tazzari C Evangelisti A Ognibene M Battistelli E Falcieri F Melchionda A Pession P Pagliaro JA McCubrey AM Martelli 2010 Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia Cancer Res 70 8097 8107 20876803 1:CAS:528:DC%2BC3cXht1yqs7fM
43. DC Cho MB Cohen DJ Panka M Collins M Ghebremichael MB Atkins S Signoretti JW Mier 2010 The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma Clin Cancer Res 16 3628 3638 20606035 1:CAS:528:DC%2BC3cXovVansbk%3D
44. M Lopez-Fauqued R Gil J Grueso J Hernandez-Losa A Pujol T Moline JA Recio 2010 The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells Int J Cancer 126 1549 1561 19810100 1:CAS:528:DC%2BC3cXhtl2itLo%3D
45. SM Maira F Stauffer J Brueggen P Furet C Schnell C Fritsch S Brachmann P Chene A De Pover K Schoemaker D Fabbro D Gabriel M Simonen L Murphy P Finan W Sellers C Garcia-Echeverria 2008 Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol Cancer Ther 7 1851 1863 18606717 1:CAS:528:DC%2BD1cXoslCgtb4%3D
46. DW McMillin M Ooi J Delmore J Negri P Hayden N Mitsiades J Jakubikova SM Maira C Garcia-Echeverria R Schlossman NC Munshi PG Richardson KC Anderson CS Mitsiades 2009 Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 Cancer Res 69 5835 5842 19584292 1:CAS:528:DC%2BD1MXosV2msbw%3D
47. MB Dilling P Dias DN Shapiro GS Germain RK Johnson PJ Houghton 1994 Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor Cancer Res 54 903 907 7508822 1:CAS:528:DyaK2cXitVyju74%3D (Pubitemid 24085438)
48. X Wan B Harkavy N Shen P Grohar LJ Helman 2007 Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism Oncogene 26 1932 1940 17001314 1:CAS:528:DC%2BD2sXjtlWgtLw%3D (Pubitemid 46474636)
49. X Wang P Yue CB Chan K Ye T Ueda R Watanabe-Fukunaga R Fukunaga H Fu FR Khuri SY Sun 2007 Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation Mol Cell Biol 27 7405 7413 17724079 1:CAS:528:DC%2BD2sXht1GltrzE (Pubitemid 350033648)
50. MR Janes JJ Limon L So J Chen RJ Lim MA Chavez C Vu MB Lilly S Mallya ST Ong M Konopleva MB Martin P Ren Y Liu C Rommel DA Fruman 2010 Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor Nat Med 16 205 213 20072130 1:CAS:528:DC%2BC3cXltlCnsQ%3D%3D
51. A Carracedo L Ma J Teruya-Feldstein F Rojo L Salmena A Alimonti A Egia AT Sasaki G Thomas SC Kozma A Papa C Nardella LC Cantley J Baselga PP Pandolfi 2008 Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J Clin Invest 118 3065 3074 18725988 1:CAS:528:DC%2BD1cXhtV2isb3P
52. PS Hammerman CJ Fox MJ Birnbaum CB Thompson 2005 Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival Blood 105 4477 4483 15705789 1:CAS:528:DC%2BD2MXks12isb8%3D (Pubitemid 40720797)
53. Z Beharry S Mahajan M Zemskova YW Lin BG Tholanikunnel Z Xia CD Smith AS Kraft 2010 The Pim protein kinases regulate energy metabolism and cell growth Proc Natl Acad Sci USA 10.1073/pnas.1013214108 21187426
54. M Lilly A Kraft 1997 Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells Cancer Res 57 5348 5355 9393759 1:CAS:528:DyaK2sXnslGqsr0%3D (Pubitemid 27516373)
55. F Zhang ZM Beharry TE Harris MB Lilly CD Smith S Mahajan AS Kraft 2009 PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells Cancer Biol Ther 8 846 853 19276681 1:CAS:528:DC%2BD1MXovFOntrw%3D
56. Z Beharry M Zemskova S Mahajan F Zhang J Ma Z Xia M Lilly CD Smith AS Kraft 2009 Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells Mol Cancer Ther 8 1473 1483 19509254 1:CAS:528:DC%2BD1MXntVKgsb8%3D
57. CJ Fox PS Hammerman CB Thompson 2005 The Pim kinases control rapamycin-resistant T cell survival and activation J Exp Med 201 259 266 15642745 1:CAS:528:DC%2BD2MXot12muw%3D%3D (Pubitemid 40189435)
58. J Tan PL Lee Z Li X Jiang YC Lim SC Hooi Q Yu 2010 B55beta-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer Cancer Cell 18 459 471 21075311 1:CAS:528:DC%2BC3cXhsValtLrO
59. PB Dennis S Fumagalli G Thomas 1999 Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation Curr Opin Genet Dev 9 49 54 10072357 1:CAS:528:DyaK1MXhsFSntLw%3D (Pubitemid 29080386)
60. J Liu PD Stevens T Gao 2010 mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells J Biol Chem 10.1074/jbc.M110.183087
61. K Murata J Wu DL Brautigan 1997 B cell receptor-associated protein alpha4 displays rapamycin-sensitive binding directly to the catalytic subunit of protein phosphatase 2A Proc Natl Acad Sci USA 94 10624 10629 9380685 1:CAS:528:DyaK2sXmtlelur0%3D (Pubitemid 27430784)
62. MB Dilling GS Germain L Dudkin AL Jayaraman X Zhang FC Harwood PJ Houghton 2002 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin J Biol Chem 277 13907 13917 11847216 1:CAS:528:DC%2BD38XjsFWnsbg%3D (Pubitemid 34967997)
63. JR Graff BW Konicek JH Carter EG Marcusson 2008 Targeting the eukaryotic translation initiation factor 4E for cancer therapy Cancer Res 68 631 634 18245460 1:CAS:528:DC%2BD1cXhtlyhurg%3D (Pubitemid 351206735)
64. Y Luo SO Marx H Kiyokawa A Koff J Massague AR Marks 1996 Rapamycin resistance tied to defective regulation of p27Kip1 Mol Cell Biol 16 6744 6751 8943329 1:CAS:528:DyaK28XntVymsL0%3D (Pubitemid 26389733)
65. TK Neklesa RW Davis 2008 Superoxide anions regulate TORC1 and its ability to bind Fpr1: rapamycin complex Proc Natl Acad Sci USA 105 15166 15171 18812505 1:CAS:528:DC%2BD1cXht1aqtbbI
66. D Trachootham J Alexandre P Huang 2009 Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8 579 591 19478820 1:CAS:528:DC%2BD1MXmsFWqsLk%3D
67. H Hosoi MB Dilling T Shikata LN Liu L Shu RA Ashmun GS Germain RT Abraham PJ Houghton 1999 Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells Cancer Res 59 886 894 10029080 1:CAS:528:DyaK1MXht1SitLY%3D (Pubitemid 29086744)
68. S Huang L Shu MB Dilling J Easton FC Harwood H Ichijo PJ Houghton 2003 Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1) Mol Cell 11 1491 1501 12820963 1:CAS:528: DC%2BD3sXltlSkurc%3D (Pubitemid 36776536)
69. Y Shi A Frankel LG Radvanyi LZ Penn RG Miller GB Mills 1995 Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro Cancer Res 55 1982 1988 7728769 1:CAS:528:DyaK2MXltlSgtLw%3D
70. M Gyrd-Hansen P Meier 2010 IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer Nat Rev Cancer 10 561 574 20651737 1:CAS:528:DC%2BC3cXpt1Gjtbw%3D
71. M Guba P von Breitenbuch M Steinbauer G Koehl S Flegel M Hornung CJ Bruns C Zuelke S Farkas M Anthuber KW Jauch EK Geissler 2002 Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 128 135 11821896 1:CAS:528: DC%2BD38Xht1equrY%3D (Pubitemid 34155123)
72. JS Carew ST Nawrocki JL Cleveland 2007 Modulating autophagy for therapeutic benefit Autophagy 3 464 467 17495516 1:CAS:528:DC%2BD2sXhtVGrtb%2FP (Pubitemid 47293728)
73. R Crazzolara KF Bradstock LJ Bendall 2009 RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia Autophagy 5 727 728 19363300 1:CAS:528:DC%2BD1MXpvFCis7k%3D
74. N Carayol E Vakana A Sassano S Kaur DJ Goussetis H Glaser BJ Druker NJ Donato JK Altman S Barr LC Platanias 2010 Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells Proc Natl Acad Sci USA 107 12469 12474 20616057 1:CAS:528:DC%2BC3cXpt1eitbk%3D
75. W Bursch A Ellinger H Kienzl L Torok S Pandey M Sikorska R Walker RS Hermann 1996 Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy Carcinogenesis 17 1595 1607 8761415 1:CAS:528:DyaK28XlsVegsLk%3D (Pubitemid 26280381)
76. T Kanzawa IM Germano T Komata H Ito Y Kondo S Kondo 2004 Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells Cell Death Differ 11 448 457 14713959 1:CAS:528:DC%2BD2cXit12ntb0%3D (Pubitemid 38489422)
77. T Kanzawa Y Kondo H Ito S Kondo I Germano 2003 Induction of autophagic cell death in malignant glioma cells by arsenic trioxide Cancer Res 63 2103 2108 12727826 1:CAS:528:DC%2BD3sXjtlGmsbk%3D (Pubitemid 36538613)
78. S Paglin T Hollister T Delohery N Hackett M McMahill E Sphicas D Domingo J Yahalom 2001 A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles Cancer Res 61 439 444 11212227 1:CAS:528:DC%2BD3MXht1Gmsr4%3D (Pubitemid 32128593)
79. Y Shao Z Gao PA Marks X Jiang 2004 Apoptotic and autophagic cell death induced by histone deacetylase inhibitors Proc Natl Acad Sci USA 101 18030 18035 15596714 1:CAS:528:DC%2BD2MXjsl2nsQ%3D%3D (Pubitemid 40054069)
80. H Takeuchi Y Kondo K Fujiwara T Kanzawa H Aoki GB Mills S Kondo 2005 Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors Cancer Res 65 3336 3346 15833867 1:CAS:528:DC%2BD2MXjt1yrs78%3D (Pubitemid 40524618)
81. K Zhu K Dunner Jr. DJ McConkey 2010 Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells Oncogene 29 451 462 19881538 1:CAS:528:DC%2BD1MXhtlers7bK
82. RK Amaravadi D Yu JJ Lum T Bui MA Christophorou GI Evan A Thomas-Tikhonenko CB Thompson 2007 Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma J Clin Invest 117 326 336 17235397 1:CAS:528:DC%2BD2sXhs1Oqsbs%3D (Pubitemid 46203961)
83. C Bellodi MR Lidonnici A Hamilton GV Helgason AR Soliera M Ronchetti S Galavotti KW Young T Selmi R Yacobi RA Van Etten N Donato A Hunter D Dinsdale E Tirro P Vigneri P Nicotera MJ Dyer T Holyoake P Salomoni B Calabretta 2009 Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells J Clin Invest 119 1109 1123 19363292 1:CAS:528:DC%2BD1MXlsFyrsLY%3D
84. JS Carew CM Espitia JA Esquivel 2nd D Mahalingam KR Kelly G Reddy FJ Giles ST Nawrocki 2010 Lucanthone: a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis J Biol Chem 10.1074/jbc.M110.151324 21148553
85. JS Carew EC Medina JA Esquivel 2nd D Mahalingam R Swords K Kelly H Zhang P Huang AC Mita MM Mita FJ Giles ST Nawrocki 2010 Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation J Cell Mol Med 14 2448 2459 19583815 1:CAS:528:DC%2BC3cXhs1Sis7zL
86. JS Carew ST Nawrocki CN Kahue H Zhang C Yang L Chung JA Houghton P Huang FJ Giles JL Cleveland 2007 Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance Blood 110 313 322 17363733 1:CAS:528:DC%2BD2sXnsVaitrw%3D (Pubitemid 47026849)
87. B Hoang P Frost Y Shi E Belanger A Benavides G Pezeshkpour S Cappia T Guglielmelli J Gera A Lichtenstein 2010 Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor Blood 116 4560 4568 20686120 1:CAS:528: DC%2BC3cXhsFGgtbvJ
88. AC Hsieh M Costa O Zollo C Davis ME Feldman JR Testa O Meyuhas KM Shokat D Ruggero 2010 Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E Cancer Cell 17 249 261 20227039 1:CAS:528:DC%2BC3cXlsVWqtLY%3D
89. QW Fan ZA Knight DD Goldenberg W Yu KE Mostov D Stokoe KM Shokat WA Weiss 2006 A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma Cancer Cell 9 341 349 16697955 1:CAS:528:DC%2BD28XltF2nsL0%3D (Pubitemid 43668732)
90. V Serra B Markman M Scaltriti PJ Eichhorn V Valero M Guzman ML Botero E Llonch F Atzori S Di Cosimo M Maira C Garcia-Echeverria JL Parra J Arribas J Baselga 2008 NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations Cancer Res 68 8022 8030 18829560 1:CAS:528:DC%2BD1cXhtF2msLrK
91. D Cirstea T Hideshima S Rodig L Santo S Pozzi S Vallet H Ikeda G Perrone G Gorgun K Patel N Desai P Sportelli S Kapoor S Vali S Mukherjee NC Munshi KC Anderson N Raje 2010 Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma Mol Cancer Ther 9 963 975 20371718 1:CAS:528:DC%2BC3cXktlCqtL4%3D
92. M Hahn W Li C Yu M Rahmani P Dent S Grant 2005 Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways Mol Cancer Ther 4 457 470 15767555 1:CAS:528:DC%2BD2MXit1Knsrk%3D (Pubitemid 40443931)
93. JR Mills Y Hippo F Robert SM Chen A Malina CJ Lin U Trojahn HG Wendel A Charest RT Bronson SC Kogan R Nadon DE Housman SW Lowe J Pelletier 2008 mTORC1 promotes survival through translational control of Mcl-1 Proc Natl Acad Sci USA 105 10853 10858 18664580 1:CAS:528:DC%2BD1cXpvFOju7c%3D
94. M Wangpaichitr C Wu M You MT Kuo L Feun T Lampidis N Savaraj 2008 Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins Eur J Pharmacol 591 124 127 18585380 1:CAS:528:DC%2BD1cXps12lsr4%3D
95. G Wei D Twomey J Lamb K Schlis J Agarwal RW Stam JT Opferman SE Sallan ML den Boer R Pieters TR Golub SA Armstrong 2006 Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance Cancer Cell 10 331 342 17010674 1:CAS:528:DC%2BD28XhtFCgsbjK (Pubitemid 44512194)
96. M Marinov A Ziogas OE Pardo LT Tan T Dhillon FA Mauri HA Lane NR Lemoine U Zangemeister-Wittke MJ Seckl A Arcaro 2009 AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001 Clin Cancer Res 15 1277 1287 19228731 1:CAS:528: DC%2BD1MXitVOktro%3D
97. HG Wendel A Malina Z Zhao L Zender SC Kogan C Cordon-Cardo J Pelletier SW Lowe 2006 Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo Cancer Res 66 7639 7646 16885364 1:CAS:528: DC%2BD28XnsFyru7w%3D (Pubitemid 44289221)
98. S Ackler Y Xiao MJ Mitten K Foster A Oleksijew M Refici S Schlessinger B Wang SR Chemburkar J Bauch C Tse DJ Frost SW Fesik SH Rosenberg SW Elmore AR Shoemaker 2008 ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo Mol Cancer Ther 7 3265 3274 18852130 1:CAS:528: DC%2BD1cXht1ensb%2FO
99. KW Kim L Moretti LR Mitchell DK Jung B Lu 2009 Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model Clin Cancer Res 15 6096 6105 19773376 1:CAS:528:DC%2BD1MXhtF2lur%2FK
100. H Huynh VC Ngo HN Koong D Poon SP Choo CH Thng P Chow HS Ong A Chung KC Soo 2009 Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma J Cell Mol Med 13 2673 2683 19220580
101. CJ Bruns GE Koehl M Guba M Yezhelyev M Steinbauer H Seeliger A Schwend A Hoehn KW Jauch EK Geissler 2004 Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer Clin Cancer Res 10 2109 2119 15041732 1:CAS:528:DC%2BD2cXisVGksrc%3D (Pubitemid 38375573)
102. D Del Bufalo L Ciuffreda D Trisciuoglio M Desideri F Cognetti G Zupi M Milella 2006 Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus Cancer Res 66 5549 5554 16740688 (Pubitemid 43927103)
103. P Frost Y Shi B Hoang A Lichtenstein 2007 AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells Oncogene 26 2255 2262 17016437 1:CAS:528: DC%2BD2sXjvVaru7g%3D (Pubitemid 46572812)
104. TL Phung K Ziv D Dabydeen G Eyiah-Mensah M Riveros C Perruzzi J Sun RA Monahan-Earley I Shiojima JA Nagy MI Lin K Walsh AM Dvorak DM Briscoe M Neeman WC Sessa HF Dvorak LE Benjamin 2006 Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin Cancer Cell 10 159 170 16904613 1:CAS:528:DC%2BD28XovVKqu74%3D (Pubitemid 44175906)
105. S Stephan K Datta E Wang J Li RA Brekken S Parangi PE Thorpe D Mukhopadhyay 2004 Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer Clin Cancer Res 10 6993 7000 15501979 1:CAS:528:DC%2BD2cXpslGluro%3D (Pubitemid 39383051)
106. CW Chiu H Nozawa D Hanahan 2010 Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis J Clin Oncol 28 4425 4433 20823411 1:CAS:528:DC%2BC3cXhsVejt7zP
107. JD Hainsworth DR Spigel HA Burris 3rd D Waterhouse BL Clark R Whorf 2010 Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma J Clin Oncol 28 2131 2136 20368560 1:CAS:528:DC%2BC3cXpsFSgsb4%3D
108. S Wedel L Hudak JM Seibel E Juengel I Tsaur A Haferkamp RA Blaheta 2011 Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells Cancer Lett 301 17 28 21122981 1:CAS:528:DC%2BC3MXhsF2ktg%3D%3D
109. Q Chang E Chen DW Hedley 2009 Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models Cancer Biol Ther 8 1893 1901 20009539 1:CAS:528:DC%2BC3cXotVynsbg%3D
110. CW Kinkade M Castillo-Martin A Puzio-Kuter J Yan TH Foster H Gao Y Sun X Ouyang WL Gerald C Cordon-Cardo C Abate-Shen 2008 Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model J Clin Invest 118 3051 3064 18725989 1:CAS:528:DC%2BD1cXhtV2isb3N
111. HM Verheul B Salumbides K Van Erp H Hammers DZ Qian T Sanni P Atadja R Pili 2008 Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors Clin Cancer Res 14 3589 3597 18519793 1:CAS:528:DC%2BD1cXmslygt7s%3D
112. J Yuan G Kroemer 2010 Alternative cell death mechanisms in development and beyond Genes Dev 24 2592 2602 21123646 1:CAS:528:DC%2BC3cXhsF2jsL3N